BCYC

BICYCLE THERAPEUTICS PLC

Nasdaq· Pharmaceutical Preparations· Inc. X0· CIK 0001761612 Biotech & Drug Discovery

$3.55 +0.00 (+0.00%)

Oct 26 4:00 PM ET · prev $3.55

Market cap

$254.8M

Micro cap

Consensus

Buy

75% Buy or better · 16 analysts

Median target

$9.50

+168% · range $5.00–14.00

Next earnings

Oct 28

in 2 days · EPS est. −$0.46

1 year

−56.3%

from $8.12 · Oct 27

30 days

−4.3%

from $3.71

52-week range

$3.38–8.76

−59% from high · low Oct 2

Avg volume 20D

475.5K

Oct 5 spike 1.84M

Short interest

3.30M

≈4.7% of shares · −0.9%

Days to cover

8.7

at average volume

Insider net

-$193.2K

0 buyers · 6 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

SecBot read MIXED 2 reports · 90 days

Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score

Avg score

·High conf. 2/2 ·Next Earnings date, Oct 28, 2026

Strongest NEUTRAL Bicycle Therapeutics reported Q2 2026 financial results with a net loss of $50.3M ($-0.72/share), narrowing…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

S Apr 2 to Apr 6 2 days of insider sells: $70.0K by 5 insiders, avg $4.94
R Apr 20 Bicycle Therapeutics announced positive Phase 1/2 clinical data for…
S Jul 2 to Jul 6 2 days of insider sells: $60.5K by 5 insiders, avg $4.28
S Oct 2 to Oct 5 2 days of insider sells: $62.8K by 6 insiders, avg $3.49

Signal stack

Where each data set points today.

InsidersBEARISH

6 insiders sold $193.2K.
InstitutionsBULLISH

Q2 2026: 14 added (0 new), 3 trimmed or exited.
AnalystsBULLISH

12 of 16 rate it Buy or better. Every target is above the price.
EstimatesRISING

Current-quarter EPS estimate −$0.519 → −$0.459 over 90 days. 2 up, 0 down in 30 days.
Short sellersSTEADY

Short interest −0.9% to 3.30M shares. 8.7 days to cover, ≈4.7% of shares.
TrendDOWNTREND

8% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
RENAISSANCE TECHNOLOGIES LLC	ADD	1,533,400	$6.5M
MARSHALL WACE, LLP	DOUBLED	797,940	$3.4M
Qube Research & Technologies Ltd	DOUBLED	775,567	$3.3M
CITADEL ADVISORS LLC	ADD	554,225	$2.3M
MILLENNIUM MANAGEMENT LLC	ADD	553,967	$2.3M
JANE STREET GROUP, LLC	ADD	392,163	$1.7M
Jump Financial, LLC	DOUBLED	167,100	$708.5K
HRT FINANCIAL LP	ADD	66,237	$280.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts

Buy 75% rate it Buy or better

Strong Buy5Buy7Hold4Sell0Strong Sell0

12-month targets · 6 analysts

$3.55 $5.00 $9.50 $14.00

Price is below the lowest target. Median implies +168%.Targets as of Oct 26, 2026.

Recent actions

Date	Firm	Action	Rating
Jul 30, 2026	Needham MAINTAIN	MAINTAIN	Buy

Insider ledger

Form 4

bought · 0 insiders

$193.2K

sold · 6 insiders

Date	Insider	Type	Value
Oct 5, 2026	Skynner Michael CHIEF SCIENTIFIC OFFICER	SELL	$1.8K
Oct 5, 2026	Hannay Michael Charles Ferguson CHIEF PROD & SUPPLY CHAIN OFF	SELL	$863.94
Oct 5, 2026	Perry Jennifer Scott Chief Operating Officer	SELL	$284.80
Oct 5, 2026	Lee Kevin CHIEF EXECUTIVE OFFICER	SELL	$5.8K
Oct 5, 2026	Thompson Travis Alvin Chief Financial Officer	SELL	$282.03
Oct 5, 2026	Perry Jennifer Scott Chief Operating Officer	SELL	$107.10
Oct 5, 2026	Perry Jennifer Scott Chief Operating Officer	SELL	$1.2K
Oct 2, 2026	Skynner Michael CHIEF SCIENTIFIC OFFICER	SELL	$6.7K

Earnings setup

Estimates

Oct 28

reports in 2 days

−$0.46

EPS estimate, this quarter

+12%

estimate change, 90 days

2↑ 0↓

revisions, 30 days

Current-quarter EPS estimate

−$0.519

90d

−$0.459

60d

−$0.459

30d

−$0.459

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.46	-$0.65–-$0.04	+0.0%	$12.2M
Next Q	-$0.41	-$0.59–$0.28	+0.3%	$1.6M
Current FY	-$2.45	-$2.80–-$1.34	+0.0%	$17.5M
Next FY	-$2.21	-$2.79–-$1.39	+0.4%	$6.7M